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Embryonic Stem Cells Improve Cardiac Function in Doxorubicin-Induced
Cardiomyopathy Mediated Through Multiple Mechanisms
Dinender K. Singla, Aisha Ahmed, Reetu Singla, and Binbin Yan
Biomolecular Science Center, Burnett School of Biomedical Sciences, College of Medicine,
University of Central Florida, Orlando, FL, USA

Doxorubicin (DOX) is an effective antineoplastic agent used for the treatment of a variety of cancers.
Unfortunately, its use is limited as this drug induces cardiotoxicity and heart failure as a side effect. There is
no report that describes whether transplanted embryonic stem (ES) cells or their conditioned medium (CM) in
DOX-induced cardiomyopathy (DIC) can repair and regenerate myocardium. Therefore, we transplanted ES
cells or CM in DIC to examine apoptosis, fibrosis, cytoplasmic vacuolization, and myofibrillar loss and their
associated Akt and ERK pathway. Moreover, we also determined activation of endogenous c-kit+ve cardiac stem
cells (CSCs), levels of HGF and IGF-1, growth factors required for c-kit cell activation, and their differentiation into cardiac myocytes, which also contributes in cardiac regeneration and improved heart function. We
generated DIC in C57Bl/6 mice (cumulative dose of DOX 12 mg/kg body weight, IP), and animals were treated
with ES cells, CM, or cell culture medium in controls. Two weeks post-DIC, ES cells or CM transplanted hearts
showed a significant ( p < 0.05) decrease in cardiac apoptotic nuclei and their regulation with Akt and ERK
pathway. Cardiac fibrosis observed in the ES cell or CM groups was significantly less compared with DOX
and cell culture medium groups ( p < 0.05). Next, cytoplasmic vacuolization and myofibrillar loss was reduced
( p < 0.05) following treatment with ES cells or CM. Moreover, our data also demonstrated increased levels
of c-kit+ve CSCs in ES cells or CM hearts and differentiated cardiac myocytes from these CSCs, suggesting
endogenous cardiac regeneration. Importantly, the levels of HFG and IGF-1 were significantly increased in
ES cells or CM transplanted hearts. In conclusion, we reported that transplanted ES cells or CM in DIC hearts
significantly decreases various adverse pathological mechanisms as well as enhances cardiac regeneration that
effectively contributes to improved heart function.
Key words: Stem cells; Heart; Doxorubicin (DOX); Apoptosis; Fibrosis

INTRODUCTION
Doxorubicin (DOX) is an antineoplastic antibiotic
vastly used antitumor agent for a diversity of malignancies
(22,27). However, the clinical use of this drug is restricted
due to a severe, dose-dependent, acute cardiotoxicity that
may progress to irreversible chronic cardiomyopathy and
congestive heart failure. DOX-induced cardiomyopathy
(DIC) has been well published in human and animal studies. Even though, the precise mechanism of DIC is unclear,
antitumor activity of DOX is relayed to be distinct from the
mechanisms of induced cardiomyopathy. DIC appears to
involve multifactorial and complex disease mechanisms;
however, oxidative stress plays a major role in this cardiotoxicity. DIC is characterized by contractile dysfunction
and rhythm disturbances that lead to congestive heart failure in a time-dependent manner (22,27). Moreover, development of heart failure includes (a) death of both cardiac
myocytes and nonmyocyte myocardial cells, (b) myofibril

loss and vacuolar degeneration, and (c) fibrosis. These
changes result in rearrangement of heart tissue, increased
wall stress, and insufficient systolic contractility in cardiac
myocytes (12,22,27,38). Importantly, the collagen synthesis
that is increased in DIC is also associated with concurrent
extracellular matrix (ECM) degradation via activation of
matrix metalloproteinases (MMPs) (12,33,38). Numerous
studies have demonstrated inhibiting doxorubicin-induced
cardiac myocyte apoptosis in DIC using various agents
such as erythropoietin and antioxidants (11–13). However,
DIC is a major health problem; therefore, accurate identification of novel therapeutic approaches is still warranted.
Over the past decade, cell transplantation studies have
demonstrated significant interest as a potential option to treat
distinct heart diseases including DIC (1,9,39). Published
studies demonstrate significant improvement in cardiac
function in DIC following adult stem cell transplantation
(1,9,39). Moreover, these studies proclaimed minimal or no
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successful engraftment of transplanted cells (1,39). There is
no data yet attainable that describes the ability of embryonic
stem (ES) cells or their factors released to repair and regenerate DIC; however, ES cells have a distinct advantage as
they are unique in the potential to differentiate into many
body cell types compared with their counterpart adult stem
cells (28). Therefore, in the present study, we hypothesized
that transplanted ES cells or their conditioned medium
(CM), containing cytoprotective factors, will inhibit DIC.
We present data in this study on transplanted ES cells or CM
that inhibit cardiac apoptosis, fibrosis, cytoplasmic vacuolization, and myofibril loss, typical characteristics of DIC.
Additionally, we also determined significant increased levels
of hepatocyte growth factor (HGF) and insulin growth factor
(IGF-1) in hearts transplanted with ES cells or CM, required
in activating c-kit+ve cardiac stem cells (CSCs). Moreover,
increased numbers of c-kit+ve CSCs were predominantly
observed in the same HGF and IGF-1 hearts. Finally, we
observed significant improvement in cardiac function following ES cells or CM transplantation, suggesting multiple
mechanisms are required to blunt DIC.
MATERIALS AND METHODS
ES Cells and Preparation of CM
Mouse ES cells expressing green fluorescence protein (GFP) were maintained using our standard protocol as previously described (30,32). In brief, cells
were plated 24 h on gelatinized tissue culture plates
in Dulbecco’s modified Eagle’s medium (DMEM)
containing essential ingredients such as fetal bovine
serum (FBS), leukemia inhibitory factor (LIF), glutamine, penicillin/streptomycin, sodium pyruvate, and
b-mercaptoethanol. For ES-CM, cell culture medium
was replaced with cell culture medium without LIF.
After 48 h, released factors containing cell super
natant was removed, filtered (0.2-mm filter, Millipore,
USA), and used to inject sterile CM as we previously
published (30,32).
Animals and Experimental Protocol
All the animals described in this study are approved
by University of Central Florida animal care committee. C57Bl6 mice were divided into five different study
groups: control, normal saline, DOX, DOX + cell culture
(CC) medium, DOX + ES cells, or DOX + CM. There
were n = 6–8 animals in each of the five study groups.
DOX was administered in three equal injections in
mice (4 mg/kg/injection IP) on alternate days over the
period of 1 week for a cumulative dose of 12 mg/kg.
For treatment groups, CC medium (400 µl/injection and
the total of three injections), ES cells (5 ´ 105 ES cells/
injection and total of three injections), or ES-CM (400
µl/injection and total of three injections) was injected
during DOX treatment on alternative days. For example,

Singla ET AL.

DOX or normal saline in controls 400 µl/injection was
given on Monday, Wednesday, and Friday, whereas
treatment groups, CC medium, ES cells, or ES-CM were
given on Tuesday, Thursday, and Saturday. After the last
injection of treatment groups, animals were examined
for heart function using echocardiography and were
sacrificed at day (D) 14 by administering pentabarbitol (40 mg/kg, IP). Furthermore, half of the heart tissue
was fixed in 4% paraformaldehye, whereas the other
half was saved in RNA later to perform biochemical and
ELISA assays.
Identification of Apoptotic Nuclei and
Caspase-3 Staining
Apoptotic nuclei in heart sections with or without cell
transplantation groups were identified using a commercially available terminal deoxynucleotidyl transferase
dUTP nick end labeling (TUNEL assay kit; TMR red;
Roche Applied Biosystems, IN, USA) as per detailed
instructions available with the kit. Moreover, we have
published this protocol in our previous studies (29).
Next, we identified colabeling of TUNEL-positive apo
ptotic nuclei with proapoptotic caspase-3 as well as with
sarcomeric cardiac a-actin to determine if apoptosis does
occur in cardiac myocytes. In brief, TUNEL-stained sections were stained with primary antibodies; active anticaspase-3 rabbit polyclonal (1:1,000; Cell Signaling)
and sarcomeric cardiac a-actin mouse monoclonal
antibodies (1:30; Sigma). Following incubations, sections were washed with PBS and labeled with secondary
antibodies: anti-rabbit Alexa 568 (Invitrogen) or antimouse Alexa 488 (MOM kit, vector laboratories). Total
nuclei were stained blue with DAPI (4′,6-diamidino2-phenylindole) present in the mounting Vectashield
medium. Positively stained cells were examined, and
photomicrographs were prepared with an Olympus fluorescence microscope and a LEICA laser scanning confocal microscope. Red stained apoptotic nuclei present in
the left ventricular area of the heart were examined, and
quantifications were determined by two blind observers
in four to five random areas in one to two heart sections
from six to eight different hearts as published (29). To
determine percentage of apoptotic nuclei per section,
we calculated using the formula: number of apoptotic
nuclei/total number of nuclei per section and then multiply by 100. Percentage of apoptotic nuclei data was
examined under 20´ magnification.
Caspase-3 Activity
Heart homogenates were prepared from different
DOX and ES cell-treated groups. Caspase-3 activity was
performed using a caspase-3 colorimetric activity assay
kit from BioVision (CITY, CA, USA) as we reported
recently (5). Protein concentrations were measured in
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the supernatant using a Bio-Rad assay. Caspase-3 activity was performed as per the instructions provided in the
kit and measured at 405 nm in a microtiter plate reader.
Caspase-3 activity was calculated and plotted in the form
of arbitrary units (A.U.).
Phosphorylated Akt Activity
Phosphorylated Akt (p-Akt) and phosphorylated extracellular signal-regulated kinases 1/2 (p-ERK 1/2) activities were examined using commercially available kits
(Exalpha Biologicals, Inc., Maynard, MA). In brief, tissues were homogenized as described beforehand, and
p-Akt and p-ERK 1/2 were quantified according to manufacturer’s instructions. The reactions were developed,
and the color reactions were measured at 450 nm using a
microtiter plate reader for each ELISA. p-Akt and p-ERK
1/2 protein data were plotted as ng/mg tissue and arbitrary units (A.U.), respectively.
Determination of HGF and IGF-1 in Heart Tissue in DIC
Hearts were isolated; homogenates were prepared with
the assay buffer provided with the kit. Using our standard
Bio-Rad assay, total protein concentrations were determined. Commercially available kits, HGF (B-Bridge
International, CA) and IGF-1 (R&D, Minneapolis, USA),
were purchased and used to measure HGF and IGF-1 levels in the DIC hearts with or without treatment groups.
These kits are based on the ELISA sandwich assay, which
was performed in accordance with the kit instructions.
HGF and IGF-1 concentrations in the samples were analyzed from the standard curve performed according to the
kit directions.
Determination of Myofibrillar Loss, Cytoplasmic
Vacuolization, and Fibrosis
Hearts were rapidly removed, placed in iced saline,
fixed in 4% buffered formalin and embedded in paraffin as described previously (29). 5-µm serial sections
were cut and deparaffinized by incubation in xylene.
Rehydration was accomplished by sequential incubation in 100%, 95%, and 70% ethanol for 5 min each
at room temperature, followed by washing in distilled
water and then phosphate-buffered saline (PBS) for
5–10 min. Heart sections were stained with commonly
used H&E and Mason’s trichrome protocols. Two to
three H&E-stained heart sections were examined completely for the evaluation of myofibrillar loss and cytoplasmic vacuolization. Qualitative data scale, developed
to determine cytoplasmic vacuolization and myofibrillar loss, varies from 0 to 2. If left ventricular (LV)
heart section showed no signs of myofibrillar loss and
cytoplasmic vacuolization then score was graded as 0,
whereas if significant portion of the section had myofibrillar loss and cytoplasmic vacuolization then slide
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was graded as 2. To determine cardiac fibrosis, sections were stained with Masson’s trichrome. Cardiac
fibrosis predominantly present in the left ventricle was
examined and quantified by measuring the total blue
area per mm2 in each section using freely available
ImageJ, NIH program.
Identification of c-Kit+ve Cells and Their Differentiation
Into Cardiac Myocytes
Sections were deparaffinized as described above. To
block nonspecific staining, sections were incubated in
humidified chamber in 10% normal goat serum (NGS)
from 30 min to 1 h at room temperature. Following incubation, sections were washed and incubated with primary rabbit polyclonal antibody anti-c-kit (Santa Cruz
Biotechnologies) and sarcmomeric cardiac α-actin mouse
monoclonal antibody (Sigma), diluted with 10% NGS,
for an hour at 37°C. Sections were washed in PBS and
incubated with secondary antibody Alexa Fluor 568 or
antimouse fluorescein isothiocyanate (FITC) available in
the MOM kit (Vector Laboratories) for 1 h. Heart sections were washed and mounted with Vectashield antifade medium (containing nuclear stain DAPI; Vector
Laboratories). Quantitative analysis of c-kit+ve cells was
determined on heart sections from four to six different hearts
using Olympus and confocal fluorescence microscope.
Echocardiographic Analysis
We routinely performed 2D echocardiography on
mice using a Sonos 5500 ultrasonograph with a 15-MHz
transducer (Philips, Andover, MA). Mice were sedated
with ketamine (100 mg/kg, IM), the chest was shaved and
maintained on a heated platform to control temperature,
and placed in a supine or left lateral decubitus position to
measure left ventricular (LV) functions using 2D echocardiography. For quantification of LV dimensions and wall
thickness, we digitally recorded 2D clips and M-mode
images in a short axis view from the mid-LV at the tips
of the papillary muscles. End diastolic and systolic LV
diameter, as well as anterior and posterior wall (AW and
PW, respectively) thickness, was measured on M-mode
images using the leading edge-to-leading edge convention. LV fractional shortening and mass were calculated
from LV cross-sectional area in 2D short axis view as
[(LVDdiastole – LVDsystole / LVDdiastole)] ´ 100 and LV mass
with formula [1.05 ´ (PWdiastole + AWdiastole + LVDdiastole)3 –
(LVDdiastole)3]. Relative wall thickness was calculated as
2 ´ PWdiastole / LVDdiastole.
Data Analysis
Values were presented as means ± SEM. One-way
analysis of variance (ANOVA) was performed followed
by Dunn’s test. Differences between values were considered statisticaly significant when p < 0.05.
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RESULTS
Effects of Transplanted ES Cells or CM on
Apoptosis in DIC
Figure 1 (A–O) shows apoptotic positive nuclei
with TUNEL staining. Right panel histogram shows
there was a significant (p < 0.05) increase in TUNELpositive nuclei in DOX and DOX + CC medium-treated
hearts compared with normal saline controls. This significant increase in apoptotic nuclei were attenuated in
DOX + CM or DOX + ES cell groups, suggesting protective effects of CM or ES cell treatments (p < 0.05)
(Fig. 1P). Next, we wanted to investigate whether
apoptotic nuclei are present in the cardiac myocytes as
well as stained positive with active caspase-3 staining,
considered as a hallmark of apoptosis. Therefore, heart
sections from all groups were stained with TUNEL,
colabeled with sarcomeric cardiac a-actin and active
caspase-3 antibody. Figure 2 (A–E) shows that TUNELstained nuclei were positive with active caspase-3 as
well as suggesting apoptosis does occur in cardiac myocytes as confirmed with sarcomeric cardiac a-actin.
Moreover, we performed a caspase-3 activity assay as
shown in Figure 2F. Significantly increased caspase-3
activity in DOX and DOX + CC hearts compared with
controls were attenuated following CM or ES cell transplantation. However, apoptosis and caspase-3 activities
were not significant between DOX + CM and DOX + ES
cell groups.
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CM or ES Cells Regulate Akt and ERK Pathways in DIC
Apoptosis has been regulated with increased or
decreased expressions of Akt and ERK signaling pathways in ischemic heart diseases (8,17,32). Therefore,
we examined effects of these pathways in the DIC and
their modulation with transplanted CM or ES cells.
Phosphorylated Akt was significantly reduced in the
DOX and DOX + CC groups compared with normal controls, suggesting a decrease in cell survival. Moreover,
hearts transplanted with CM or ES cells had significant
increased activation of p-Akt compared to DOX and
DOX + CC (Fig. 3A). Moreover, our data suggest phosphorylated ERK1/2 is significantly increased in DOX and
DOX + CC groups compared with control. A significant
decrease in ERK1/2 was observed in hearts transplanted
with CM or ES cells (p < 0.05) (Fig. 3B).
CM or ES Cells Inhibit Fibrosis, Cytoplasmic
Vacuolization, and Myofibrillar Loss
To determine the effect of transplanted CM or ES
cells on cardiac fibrosis, we stained heart sections with
Masson’s trichrome. In Figure 4 (A–E), the blue areas
show fibrotic tissue present in the DOX-treated hearts
with or without CM or ES cells. Our quantitative data
suggest that DOX and DOX + CC hearts demonstrated a
significant (p < 0.05) increase in blue area, an indicative of
cardiac fibrosis (Fig. 4F). However, this increased fibrosis was reduced following CM or ES cell transplantation

Figure 1. Transplanted conditioned medium (CM) or embryonic stem (ES) cells inhibit cardiac myocyte apoptosis at 2 weeks postdoxorubicin-induced cardiomyopathy (DIC). Representative photomicrographs of total nuclei stained with DAPI in blue (A–E) and
terminal deoxynucleotidyl transferase dUTP nick end labeling (TUNEL)-stained apoptotic nuclei in red (F–J) and merged nuclei
in pink (K–O); scale bar: 50 µm. Right: histogram (P) shows quantitative apoptotic nuclei per section from control (C), DOX (D),
D + culture medium (D + CC), D + CM, and D + ES cell groups. Data are from the n = 6–9 animals (*p < 0.05 compared to C; #p < 0.05
vs. D and D + CC).
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Figure 2. Effects of transplanted CM or ES cell on cardiac myocyte apoptosis and caspase-3 activity. Representative photos of heart
section labeled with sarcomeric cardiac α-actin (A), apoptotic nuclei stained with TUNEL in purple (B), section stained with active
caspase-3 antibody (C), total nuclei stained with DAPI in blue (D), and merged image (E) demonstrating apoptosis appearing in cardiac myocytes and positive with active caspase-3. Boxed area in (E), demonstrates colocalization of sarcomeric cardiac α-actin, active
caspase-3 (yellow area), TUNEL-positive nucleus, and DAPI. Scale bar: 25 µm. Bottom right histogram (F) shows total apoptotic
nuclei from five to eight different animals each group (*p < 0.001 vs. C, #p < 0.05 vs. D and D + CC). A.U., arbitrary units.

Figure 3. Phospho-Akt and extracellular signal regulated kinase (ERK) alterations following CM or ES cell transplantation in the DIC.
(A) Performed quantitative analysis of phospho-Akt regulation. (B) Quantitative levels of phosphorylated ERK upregulation (*p < 0.05
compared to C; #p < 0.05 vs. D and D + CC). Data are from heart homogenates of n = 4–6 animals/group. A.U., arbitrary units.
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Figure 4. Effects of transplanted CM or ES cell on cardiac fibrosis. Photomicrographs show histological sections stained with Mason’s
trichrome after 2 weeks of DOX treatment of different hearts from each group. Blue area shows extent of fibrosis in different conditions: control, C (A); DOX, D (B); D + CC (C); D + CM (D); and D + ES cells (E). Scale bar: 50 µm. (F) Histogram shows quantitative
cardiac fibrosis in post-DIC with or without treatment groups. Data are from six to eight animals (*p < 0.05 compare to C; #p < 0.05 vs.
D and D + CC).

(Fig. 4F). Therefore, relative increased amounts of viable
cardiac muscle were observed in the DOX + CM or ES
cells (Fig. 4D, E) compared with DOX or DOX + CC
groups (Fig. 4B, C).
Cyoplasmic vacuolization and myofibrillar loss, a
well-recognized characteristic of DIC, were examined to
strengthen our findings. In normal saline-treated control,
hearts show full-length cardiac myocytes with intact cytoplasmic structure as well as well-organized myofibrillars
(Fig. 5A). In contrast, DOX- or DOX + CC-treated hearts
demonstrate clear evidence of loss of cytoplasm as well
as myofibrils in many cardiac myocytes (Fig. 5B, C), and
this increased cytoplasmic vacuolization and myofibrillar loss was significantly reduced following CM or ES
cells treatments (Fig. 5D, E). Moreover, our semiquantitative data suggest significant (p < 0.05) increase in
cytoplasmic vacuolization and myofibrillar loss in DOX
and DOX + CC hearts (Fig. 5F, G). Following treatments
with CM or ES cells in DIC, hearts showed significantly

reduced amounts of cytoplasmic vacuolization and
myofibrillar, suggesting a decrease in cardiomyopathy
(Fig. 5F, G).
c-Kit+ve Cells and Their Progenitor Cells Following CM
or ES Cell Transplantation
To determine activated cardiac endogenous c-kit+ve
cells and their differentiation into cardiac myocytes to
define their role in cardiac regeneration, we examined
c-kit+ve cells and their colabeling with sarcomeric cardiac a-actin to stain cardiac myocytes in heart sections
with or without CM or ES cell transplantation in DIC.
Figure 6 (A–D) shows positively stained c-kit+ve cells as
well as c-kit+ve cells combined with cardiac myocytespecific sarcomeric cardiac a-actin, suggesting some
of the c-kit+ve cells differentiate into cardiac myocytes.
Quantitative c-kit+ve cells in DOX or DOX + CC significantly increased (p < 0.05) compared with normal
saline controls, suggesting injury released cytokine
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Figure 5. Effects of transplanted CM or ES cell on cytoplasmic vacuolization and myofibrillar loss. Photomicrographs show histological sections stained with H&E staining after 2 weeks of DOX treatment of different hearts from each group. In the representative
enlarged area, the arrow head indicates cytoplasmic vacuolization whereas the arrow shows myofibrillar loss. These cytoplasmic
vacuolization and myofibrillar loss areas in cardiac myocytes were determined in different conditions: C (A), D (B), D + CC (C),
D + CM (D), and D + ES cells (E). Scale bar: 50 µm. (F) Histogram shows semiquantitative cytoplasmic vacuolization. (G) Determines
myofibrillar loss in post-DIC with or without treatment groups. Data are from five to eight animals (*p < 0.05 compare to C; #p < 0.05 vs.
D and D + CC).

and growth factors may have triggered c-kit+ve cells
(Fig. 6E). Moreover, c-kit+ve cells were further significantly increased in CM or ES cells groups compared
with respective controls (Fig. 6E).
Levels of HGF and IGF-1 Following CM or
ES Cells Transplantation
Following an increase in c-kit+ve cells in CM or ES
cell groups in DIC, we determined the levels of HGF
and IGF-1, a growth factor considered to be an activator of c-kit+ve cells. Our data demonstrate that heart tissue homogenates prepared from CM- or ES cell-treated
hearts have significant increased levels of HGF and IGF-1
(Fig. 6F, G). Thus, increased HGF and IGF-1 levels suggest that these factors released into DIC hearts following
CM or ES cell transplantation may also contribute to the
stimulation and differentiation of the CSCs that play a
role in regeneration.
No Evidence of Teratoma Formation Following ES Cell
Transplantation in DOX Cardiomyopathy
To determine whether teratoma were present following
ES cell transplantation, H&E and Masson’s trichromestained heart, lung, and liver sections were examined at
2 weeks post-DOX treatment. No evidence of teratoma

formation was observed at 2 weeks in the heart, lung,
and liver. Figure 7 is representative of these sections at
2 weeks post-DOX-treated hearts.
Improvement in LV Function Following CM or
ES Cells Transplantation
M-mode echocardiography was used to determine the
effect of CM or cell transplantation on LV size and function in mice at 2 weeks post-DOX treatment. Fractional
shortening was improved by CM and ES cell transplanted hearts compared with DOX or DOX + CC groups
(Fig. 8A). Additionally, CM and ES cells also demonstrated significantly improved ejection fraction (Fig. 8B).
Moreover, the increased LVIDs in DOX and DOX + CC
groups was significantly (p < 0.05) (Fig. 8C) blunted following CM or ES cell transplantation.
DISCUSSION
Cell therapy has been widely examined in various animal
and human cardiac diseases (9,15,16,20,21,24,25). Animal
studies have successfully manifested significant improvement in cardiac function (24,25). Human embryonic stem
cell-derived vascular cells and bone marrow-derived multipotent progenitor cells following transplantation in the
porcine infarcted heart improved cardiac function (36,37).
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Figure 6. Effects of transplanted CM or ES cell on cardiac stem cells (CSCs) and their differentiation into cardiac myocytes. Heart
section stained with sarcomeric cardiac α-actin showing all stained cardiac myocytes in green (A), resident CSCs were identified by
anti-c-kit antibody labeling in red (B), and nuclei are stained with DAPI in blue (C). Merged image indicating presence of CSCs and
the positive staining with cardiac α-actin (D, green, red, and blue). Bottom left arrow indicates differentiated CSCs, whereas dashed
arrow in right top panel shows CSCs positive with c-kit staining. Scale bar: 50 µm. (E) Histogram shows quantitative cardiac progenitor
cells in post-DIC hearts from C, D, D + CC, D + CM, and D + ES cells groups. Data are from four to five animals (*p < 0.05 compared to
C; #p < 0.05 vs. D and D + CC). (F) Histogram shows hepatocyte growth factor (HGF) data analysis performed in different DIC groups.
(G) Histogram shows levels of insulin-like growth factor (IGF)-1 in the DIC hearts with or without treatment groups. Data are from
four to five animals (*p is nonsignificant compared to C; #p < 0.05 vs. D and D + CC).

Moreover, bone marrow-derived stem cells or combined
therapy with cardiomyocytes inhibits doxorubicin-induced
heart failure in rabbits (7,15,16). Unfortunately, adult stem
cell transplanted clinical studies provided contentious
reports on the improvement of cardiac function (9,21).
Therefore, the use of ES cells may be an optimal cell
type, with a wide potential for cell differentiation and
unique in characteristics as released factors from these
cell types are quite different compared with adult stem
cells. Moreover, there is no data yet available that determines the effects of CM or ES cells on DIC. Therefore,
we hypothesize that transplanted CM or ES cells will

inhibit multiple pathological mechanisms in DIC and will
improve associated cardiac function.
In the present study, we used a very clinical relevant
DIC cardiomyopathy model, which is well established
by various investigators (4,26,27). Importantly, DOX as
administered in the present study demonstrates cardiac
apoptosis, regulation of apoptotic-mediated Akt/ERK pathways, cardiac fibrosis, cytoplasmic vacuolization, myo
fibrillar loss, and decrease in cardiac function in terms of
fractional shortening and ejection fraction as deliberated
by echocardiography. These alterations construct DIC as
observed in cancer patients treated with DOX (4,26,27).
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Figure 7. Representative photomicrographs of H&E-stained heart sections from DOX + ES cell group shows no evidence of teratoma
formation in the heart, lung, and liver post-DIC at 2 weeks. Original magnification: 10´.

Therefore, we report that the DIC model in the present
study is in accordance with published reports (4,26,27).
The major findings of the present study is that transplantation of the CM or ES cells in DIC results in significant
attenuation of various pathological mechanisms such as
(1) inhibition of cardiac myocyte apoptosis, (2) inhibited
apoptosis involving phosphoinositol-3-kinase (PI3K)/Akt
and ERK pathways, (3) significantly attenuated cardiac
fibrosis, (4) inhibition of cytoplasmic vacuolization and
myofibrillar loss, (5) activation of c-kit+ve CSCs and their
role in cardiac regeneration, (6) increased levels HGF and
IGF-1 growth factors required for c-kit+ve cells activation,
and (7) ultimately improved cardiac function.
Apoptosis is an elemental part of normal organ development (2,14). Recently, presence of apoptosis has been
notified to regulate various diseases, including DIC (2,
13,14). We and others have reported that apoptosis is a
significant contributor in the development and progression of DIC (4,13,14,22). The data on apoptosis in this
investigation were established with TUNEL staining as

well as by measuring caspase-3 activities. We also demonstrate that hearts transplanted with CM or ES cells have
a significantly reduced amount of apoptosis. Additionally,
we show that apoptosis does occur in cardiac myocytes
as evidenced by colabeling of active caspase-3 with
TUNEL-positive nuclei. Moreover, our data authenticate
with the previously published data in DIC and infarcted
hearts (2,4,13,14,22). As per the best of our knowledge,
we are the first to report that transplanted CM or ES cells
suppress apoptosis in DIC.
Next, to comprehend mechanisms by which CM or
ES cells inhibit apoptosis in DIC, we explored the role
of PI3K/Akt and ERK pathways. The PI3K/Akt pathway controls regulation of various cellular processes,
including cell growth, proliferation, and survival (6,23).
In the present study, we imply that DOX treatment significantly decreases levels of Akt. This reduction in Akt
was reversed following treatment with CM or ES cells,
suggesting a role of Akt in cell survival in DIC hearts.
In contrast, the role of ERK pathway is not well defined

Figure 8. Transplanted CM or ES cells in DIC improve cardiac function at 2 weeks. (A) Average echocardiographic left ventricular
fractional shortening. (B) Ejection fraction. (C) Left ventricular interior systolic diameter (LVIDs) for different treatment groups.
*p < 0.05 compared to C; #p < 0.05 versus D and D + CC.
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in assorted heart diseases and considered controversial
as it has been shown to be actively involved in cell survival, hypertrophy, and cell death (18,23,32). However,
the expression levels of ERK1/2 have been increased in
the rat hearts at 4 h post-DOX treatment, whereas this
level was decreased at 24 h and 3 weeks posttreatment
(19). Our data suggest upregulation of ERK pathway in
DOX-treated hearts, suggesting ERK may induce hypertrophy or cell death at 2 weeks in DIC. Interestingly, this
increase in ERK pathway was significantly reversed in
the hearts treated with CM or ES cells. Varied difference
in ERK1/2 in post-DIC can be explained as (1) we used
injected DOX 12 mg/kg cumulative dose over the period
of 1 week whereas previous report injected 15 mg/kg
over the period of 2 weeks (19), which may have generated some variation in the induced cardiomyopathy,
which also alters cell signaling. Moreover, authors examined levels of ERK1/2 at 1–24 h and 3 weeks post-DIC
(19) compared with our study as we report ERK1/2 levels
at 2 weeks post-DIC.
Next, we scrutinized whether transplanted CM or ES
cells can inhibit cardiac fibrosis in the post-DIC hearts.
Cardiac fibrosis, a major contributor to end-stage heart
failure, is the result of heightened levels of various proteinases such as MMPs as well as a decrease in their inhibitors
(tissue inhibitor metalloproteinases, TIMPs), which leads
to ECM degradation, collagen protein deposition, hardening of the contractile heart muscle, and eventually, cardiac
dysfunction (10). We report in the current study that fibrosis considerably exists in DIC hearts. However, presence
and amount of fibrosis in DIC compared with infarcted
hearts is substantially different (10). Observed fibrosis in
the DIC hearts was patchy and widely distributed. In contrast, infarcted hearts exhibit a transmural infarction and
significant extent of fibrosis in the confined area (10). The
accurate mechanism for the stimulation of fibrosis in the
DIC hearts remains obscure, whereas transforming growth
factor b1 (TGF-b1) actively induces fibrosis in the infarcted
hearts (10). Next, our data for the first time reports that cardiac fibrosis in the DIC hearts was significantly attenuated
following CM or ES cell transplantation. We published
recently that factors released from ES cells contain antifibrotic factor TIMP-1 and inhibit apoptosis in the H9c2
cells (30,32). We also published that apoptosis and fibrosis
in the infarcted hearts was significantly reduced following CM transplantation (31). Moreover, inhibited apoptosis in the H9c2 cells was mediated by Akt pathway but
not by ERK pathway (32). However, we suggest that DIC
involves both Akt and ERK pathways in the regulation of
cardiac remodeling in the present study. Therefore, this
raises further questions whether inhibited apoptosis and
fibrosis in DIC following CM or ES cell transplantation
involves similar mechanisms.
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Cytoplasmic vacuolization and myofibrillar loss in cardiac myocytes is well established, and recorded characteristics of DIC were ascertained in animal models and patients
(26,27). Our present study also demonstrates the appearance of cytoplasmic vacuolization and myofibrillar loss in
DIC. Next, we scrutinized the effects of transplanted CM
or ES cells in DIC. We showed that CM or ES cells significantly inhibit cytoplasmic vacuolization and myofibrillar
loss in DIC compared with respective controls. Our data
are in compliance with the previously published report on
the carbon monoxide/heme oxygenase (CO/HO) system
that inhibits cytoplasmic vacuolization and myofibrillar
loss in DIC (34). In the present study, we confirmed evidence of cytoplasmic vacuolization and myofibrillar loss
and extended our findings by proving for the first time that
CM or ES cells attenuate cytoplasmic vacuolization and
myofibrillar loss in the DIC.
In our present study, we were unable to identify transplanted ES cells in the heart (data not shown); however,
there were significant improvement in cardiac function,
and therefore, we examined the role of c-kit+ve CSCs. We
proposed that autocrine or paracrine factors released from
ES cells will activate and differentiate resident CSCs
into mature cardiac cell types and regenerate the DOXinjured myocardium. CSCs are undifferentiated, selfrenewing, clonogenic, and capable of differentiating into
all three major heart cell types both in vitro and in vivo
(3). These cells have been identified and proven to regenerate infarcted myocardium (3). In the present study, we
demonstrate increased levels of c-kit+ve CSCs following
CM or ES cell transplantation compared with their controls. Our data are in accordance with the previously published studies showing c-kit+ve cells in the infarcted heart
were up regulated and differentiated into cardiac myocytes following treatment with HGF and IGF-1 growth
factors (35). Therefore, we extended our findings and
determined whether levels of HGF and IGF-1 are being
affected in the DIC with or without CM or ES cell treatment. To our surprise, we observed significant increased
levels of HGF and IGF-1 growth factors in CM and ES
cell-treated hearts compared with DOX, DOX + CC, and
normal saline groups, suggesting these released factors
might have played a significant role in their activation.
Therefore, further studies are required to determine if
more than two growth factors reported in this study are
involved in the inhibition of multiple pathological conditions observed in DIC.
Moreover, we determined whether transplantation of
CM or ES cells contributes to improved cardiac function
in DIC. In the present study, we have demonstrated that 2
weeks post-DIC, mice transplanted with CM or ES cells
had significantly improved cardiac function compared
with DIC.
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In conclusion, this is the first study proposing that
CM or ES cells have the competence to inhibit multiple pathological conditions such as cardiac myocyte
apoptosis, Akt and ERK pathways, cardiac fibrosis,
cytoplasmic vacuolization, and myofibrillar loss as well
as upregulation of c-kit+ve CSCs and their differentiation into cardiac myocytes along with improved cardiac
function in DIC.
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